Phaseline

Companies › Vaxiion Therapeutics

Vaxiion Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VAX014
Recombinant bacterial minicells designed to kill tumor cells following intratumoral inject
–Phase 1Advanced Solid TumorAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05901285VAX014Phase 1Advanced Solid TumorOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.